a $475 million partnership - only if ADXS can deliver; so till then do not count the chicken before they hatch. If the market were to go by your thought process, then the market cap would be closer to 475 million, not 100 million.
submission for approval - after a delay and Tony telling us that it would be filed by EOY 2017, only to see the change in plans a couple of days later in a pps where it was mentioned that it would be done in Q1, 2018. i understand, no big deal, but just pointing the fact about management. Submission for approval does not mean much until it is approved and we are far away from approval. There is probably a high chance of approval - you know better than me, but there is no 100% certainty and it is still a long way. Moreover, Ken's decision can have an impact.
Two techs on the bleeding edge of immunotherapy - yes, bleeding edge, still a long, long way to go. Years and not few months. AXAL was bleeding edge and now on the back burner.
After letting the world know last year that the company has enough cash to last till end of 2018, why did they sell 20% of the company to raise less than 20 million dollars?
HER2 was a big one - now shelved and put up for sale since 10 months - where is the money, any offers?
Anal cancer trial - much fanfare - what happened ?? No money to run it further?
They are yet to get to FDA about the hold? what are they waiting for - the 100+ employee workforce waiting Saturn to make an entry deep into Sagittarius after the retrograde into Scorpio?. Irony is many here were blaming FDA for the delay in lifting the hold.
Where is the much touted millions pouring in, from royalty and one time payment for Canine Osteosarcoma?
What about the India trial and its outcome?
Noting can be undone now that it has come to this. You can defend science with your expertise. You cannot defend management with your argument.
News 
Market Data 
Discover 
AI
